Introduction
============

Glioblastoma multiforme (GBM) is the most common and the most invasive subtype of brain cancer; it is characterized by symptoms that include personality changes, headaches, nausea and unconsciousness ([@b1-mmr-19-03-1613],[@b2-mmr-19-03-1613]). GBM originates from normal brain cells or low-grade astrocytoma, and may be induced by genetic disorders and radiation exposure ([@b3-mmr-19-03-1613],[@b4-mmr-19-03-1613]). Clinical techniques for the treatment of GBM include surgery combined with radiation therapy or chemotherapy; however, the survival benefit is limited to \~12-15 months, or even shorter if the disease recurs ([@b4-mmr-19-03-1613]).

Gene therapy is a novel strategy for treating cancers ([@b5-mmr-19-03-1613]). Transient receptor potential genes are overexpressed in GBM, which promote the survival of patients ([@b6-mmr-19-03-1613],[@b7-mmr-19-03-1613]). It has been previously reported that low expression of B cell-specific Moloney murine leukemia virus integration site 1 suppresses proliferation and promotes apoptosis of U251 GBM cells, and enhances the chemosensitivity of these cells to cisplatin ([@b8-mmr-19-03-1613],[@b9-mmr-19-03-1613]). The expression level of epidermal growth factor-containing fibulin extracellular matrix protein 1 (*EFEMP1*) was associated with the survival of patients with GBM treated with temozolomide (TMZ) ([@b10-mmr-19-03-1613]); thus, *EFEMP1* is considered a target for overcoming TMZ-resistance in GBM. Enhancer of zeste homolog 2 (*EZH2*) overexpression was associated with tumor grade and predicts short overall survival in patients with GBM ([@b11-mmr-19-03-1613]); thus, *EZH2* may be a promising prognostic factor and therapeutic target for patients. Additionally, HOX transcript antisense RNA (*HOTAIR*) overexpression was associated with poor outcome in patients with GBM, and *HOTAIR* may be a therapeutic molecular target for this disease ([@b12-mmr-19-03-1613],[@b13-mmr-19-03-1613]). O-6-Methylguanine-DNA methyltransferase (*MGMT*) methylation status and mutations in the isocitrate dehydrogenase 1 (*IDH1*) gene are two known clinicopathological factors linked to overall survival of patients with GBM ([@b14-mmr-19-03-1613]). *MGMT* methylation is significantly associated with the clinical prognosis of GBM ([@b15-mmr-19-03-1613]); *IDH1* is a prognostic marker of GBM, and mutations in this gene diminish the malignant progression of glioma ([@b16-mmr-19-03-1613]). In addition, high expression of interleukin-13R mRNA is strongly associated with poor prognosis of GBM ([@b17-mmr-19-03-1613]). POZ/BTB and AT hook-containing zinc-finger 1 is another prognostic marker of GBM; it is overexpressed in GBM-derived glioma-initiating stem cells, and is associated with the characteristic stem cell capacity to grow as neurospheres *in vitro* ([@b18-mmr-19-03-1613]). Despite this collective knowledge, the genes involved in the prognosis of GBM have not been comprehensively reported.

In 2008, Murat *et al* ([@b19-mmr-19-03-1613]) established the GSE7696 gene expression profile, and demonstrated that high expression levels of epidermal growth factor receptor and stem cell-related 'self-renewal' signature are involved in the resistance to concomitant chemoradiotherapy of GBM. In 2011, Lambiv *et al* ([@b20-mmr-19-03-1613]) used the GSE7696 data set to explore the action mechanism of tumor suppressor gene Wnt inhibitory factor 1 (*WIF1*) in GBM models, and concluded that WIF1 may have a tumor suppressive role in GBM through senescence.

However, this data set has not been fully explored. Using the GSE7696 data, additional key genes associated with the prognosis of GBM were investigated using comprehensive bioinformatics methods, such as survival analysis, enrichment analysis and hierarchical clustering. Results from the present study provided novel insights into the prognosis of GBM and may aid in the development of novel therapeutic approaches.

Materials and methods
=====================

### Data source

The GSE7696 microarray data set, based on the GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array (Thermo Fisher Scientific, Inc.) platform, along with the corresponding clinical information was downloaded from the Gene Expression Omnibus database ([www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)). The data set included 10 recurrent GBM tissue samples (2 females and 8 males; mean age, 51.31 years), 70 primary GBM tissue samples (19 females and 51 males; mean age, 48.07 years) and 4 normal brain tissue samples (sex and age information not available). All patients participated in a phase II or randomized phase III trial ([@b21-mmr-19-03-1613],[@b22-mmr-19-03-1613]), with informed consent provided. The GSE7696 data set is available and the study was approved by the local ethics committee ([@b19-mmr-19-03-1613]).

### Selection of probes with expression changes in primary GBM tissue samples

The normalized data of GSE7696 were obtained, and the primary GBM tissue samples data were selected to use in the present study. Firstly, the unloaded probes were removed. Subsequently, the probes with varied expressions among 70 different patients with primary GBM were identified by the following steps. Firstly, the variance in probe expression level in each sample was calculated, and probes with variance \<20% of the total probe variance were excluded. Secondly, the median probe expression in each sample was calculated and, as in the prior step, probes with a value \<20% of the total median probe expression were removed. Finally, the probes with expression changes among these primary GBM tissue samples were selected.

### Survival analysis and pathway enrichment analysis

Using the 'survival' package ([@b23-mmr-19-03-1613]) in R ([www.r-project.org](www.r-project.org)), univariate survival analysis was conducted for the above probes with expression changes, and those with P\<0.05 were considered as seed genes. The Kyoto Encyclopedia of Genes and Genomes (KEGG; [www.genome.ad.jp/kegg](www.genome.ad.jp/kegg)) is a database used to search for gene functions, connecting genomic with functional information ([@b24-mmr-19-03-1613]). Using the DAVID database ([david.abcc.ncifcrf.gov](david.abcc.ncifcrf.gov)) ([@b25-mmr-19-03-1613]), KEGG pathway enrichment analysis was performed for the seed genes to explore their functions. The categories with P\<0.05 were considered to indicate a statistically significant difference.

### Screening of prognostic feature genes, unsupervised hierarchical clustering and analysis of prognostic characteristics

Using the 'rbsurv' package in R ([bioconductor.org/packages/release/bioc/html/rbsurv.html](bioconductor.org/packages/release/bioc/html/rbsurv.html)) ([@b26-mmr-19-03-1613]), robust likelihood-based survival modeling was constructed to identify prognostic feature genes ([@b27-mmr-19-03-1613]). The samples were classified based on the expression profiles of the prognostic feature genes using unsupervised hierarchical clustering ([@b28-mmr-19-03-1613]). Thereafter, the prognostic differences among the classified samples were analyzed by the Kaplan-Meier survival analysis ([@b29-mmr-19-03-1613]). The expression differences of the feature genes between primary GBM and normal samples were analyzed; and the scatter plot of the gene expression levels were drawn using the corrplot package (<https://cran.r-project.org/web/packages/corrplot/vignettes/corrplot-intro.html>) in R (version 3.4.4).

### Functional and pathway enrichment analysis for the feature genes

The Gene Ontology (GO) database ([www.geneontology.org](www.geneontology.org)) is used to predict potential functions of genes and their products ([@b30-mmr-19-03-1613]). The prognostic feature genes were examined with GO functional and KEGG pathway enrichment analysis by the 'clusterProfiler' package in R ([bioconductor.org/packages/release/bioc/html/clusterProfiler.html](bioconductor.org/packages/release/bioc/html/clusterProfiler.html)), with the threshold q-value \<0.05 ([@b31-mmr-19-03-1613]).

### Multivariate survival analysis

The prognostic feature genes underwent multivariate survival analysis to check their overall influences on prognosis. In addition, the 'survivalROC' package in R ([cran.r-project.org/web/packages/survivalROC/index.html](cran.r-project.org/web/packages/survivalROC/index.html)) was used to draw the receiver operating characteristic (ROC) curve and calculate the area under the ROC curve (AUC) ([@b32-mmr-19-03-1613]). Specifically, the survivalROC package was used to calculate the 'true positive rate' and 'false positive rate' of each sample, and the differences between the 'true positive rate' and 'false positive rate' for each sample were subsequently calculated. The sample with the smallest difference value was set as the cut-off in the multifactorial cox regression analysis, and samples with a higher value than this cut-off were deemed as the high-risk group, while those with a lower value were the low-risk group.

### Validation of the prognostic feature genes using an independent data set

The GBM dataset in The Cancer Genome Atlas (TCGA; [cancergenome.nih.gov](cancergenome.nih.gov)) database (downloaded in January 27, 2015; based on the Illumina HiSeq platform, and included RNA-sequencing data in level 3 and clinical follow-up data) was obtained to validate the prognostic feature genes. The 172 samples in the data set comprised 13 recurrent GBM samples, 154 primary GBM samples and 5 adjacent normal tissue samples. Of the 154 primary GBM samples, 2 samples had no survival information. Finally, 152 primary GBM samples were selected for analysis. The data were transformed using log~2~(x+1), followed by Cox regression analysis using the 'survival' package in R to compare the differences of prognosis and recurrence among the samples in different groups. Differences in the identified factors (age and sex distribution) were assessed using R software. The Mann-Whitney test analysis was performed using the respective internal function in R, 'wilcox.test'. The χ^2^ value was calculated using the 'chisq.test' function in R.

Results
=======

### Survival analysis and pathway enrichment analysis for seed genes

The bioinformatics analysis process used in the present study is outlined in [Fig. 1](#f1-mmr-19-03-1613){ref-type="fig"}. Following calculation of the variance and median for the probes in the 70 primary GBM, a total of 38,370 probes with expression changes were identified. Based on the univariate survival analysis using the 'survival' package, a total of 1,785 gene probes significantly correlated with prognosis of GBM were selected as seed genes. KEGG pathway enrichment analysis identified six pathways that were significantly enriched for these seed genes, including 'ribosome', 'regulation of actin cytoskeleton', 'endometrial cancer', 'pathways in cancer', 'amino sugar and nucleotide sugar metabolism' and 'non-small cell lung cancer' ([Table I](#tI-mmr-19-03-1613){ref-type="table"}).

### Screening of prognostic feature genes, unsupervised hierarchical clustering and analysis of prognostic characteristics

Robust likelihood-based survival modeling identified 13 prognostic feature genes from the 1,785 seed genes, including collagen type XXVIII α1 chain (*COL28A1*), PDS5 cohesin-associated factor A (*PDS5A*; also known as sister chromatid cohesion protein 112), zinc-finger DHHC-type containing 2 (*ZDHHC2*), zinc-finger protein 24 (*ZNF24*), myosin VA (*MYO5A*) and myeloid/lymphoid or mixed-lineage leukemia translocated to 4 (*MLLT4*) ([Table II](#tII-mmr-19-03-1613){ref-type="table"}). Unsupervised hierarchical clustering was conducted for these 13 prognostic feature genes. A heat map demonstrated that these genes may be used to classify the 70 primary GBM samples into two clusters: Cluster 1 contained 51 samples and Cluster 2 contained 19 samples ([Fig. 2](#f2-mmr-19-03-1613){ref-type="fig"}). Subsequently, Kaplan-Meier survival analysis was used to analyze the prognostic differences between the two clusters. Patients in the Cluster 1 and in Cluster 2 had significant differences in their prognosis, which indicated that the 13 prognostic feature genes may effectively differentiate between high-risk and low-risk patients in a clinical setting ([Fig. 3A](#f3-mmr-19-03-1613){ref-type="fig"}). In addition, the expression levels of the 13 prognostic feature genes were relatively low, which suggested that they had low redundancy ([Fig. 3B](#f3-mmr-19-03-1613){ref-type="fig"}).

### Functional annotation of prognostic feature genes

Using the 'clusterProfiler' package, functional annotation of the prognostic feature genes were conducted. The results identified three genes, including, natriuretic peptide receptor 3 (*NPR3*), ANKH inorganic pyrophosphate transport regulator and OTU deubiquitinase, ubiquitin aldehyde binding 1 (*OTUB1*) were significantly enriched in functions, including 'natriuretic peptide receptor activity', 'inorganic phosphate transmembrane transporter activity' and 'NEDD8-specific protease activity', respectively. In addition, myeloid/lymphoid or mixed-lineage leukemia translocated to 4 (*MLLT4*; also known as afadin, adherens junction formation factor) was indicated to be involved in six KEGG pathways, including 'adherens junction', 'leukocyte transendothelial migration', 'tight junction', 'cAMP signaling pathway', 'Rap1 signaling pathway' and 'Ras signaling pathway'. *COL28A1, PDS5A, ZDHHC2* and *MYO5A* were enriched in 'collagen biosynthesis and modifying enzymes', 'separation of sister chromatids', 'surfactant metabolism' and 'regulation of actin dynamics for phagocytic cup formation' pathways, respectively.

### Multivariate survival analysis

To check the overall influence of the prognostic feature genes on prognosis, multivariate survival analysis was carried out. These genes were classified as having a positive effect on prognosis (area under the ROC curve=0.826) for the 70 primary GBM samples ([Fig. 4A](#f4-mmr-19-03-1613){ref-type="fig"}). Furthermore, Kaplan-Meier survival analysis demonstrated that the samples in the high-risk and low-risk groups differed significantly in their prognosis (P=5.67×10^−12^; [Fig. 4B](#f4-mmr-19-03-1613){ref-type="fig"}), which indicated that the 13 prognostic feature genes may effectively distinguish samples with a different prognostic risk.

### Validation of the prognostic feature genes using another independent data set

The GBM data set was downloaded from the TCGA database and used to validate the prognostic feature genes. Survival analysis demonstrated that the 13 prognostic feature genes had good classification effects on samples in the validation data set (area under the ROC curve =0.886) ([Fig. 5A](#f5-mmr-19-03-1613){ref-type="fig"}). The high-risk and low-risk groups differed significantly in their prognosis (P=5.00×10^−5^; [Fig. 5B](#f5-mmr-19-03-1613){ref-type="fig"}). Furthermore, age distribution analysis of the classified primary GBM samples demonstrated that samples in the high-risk and low-risk groups differed significantly in age, with the high-risk group being older than the low-risk group (61.54 vs. 56.96; P=0.04396; [Table III](#tIII-mmr-19-03-1613){ref-type="table"}). There was no significant difference concerning sex distribution of the classified samples.

Discussion
==========

In the present study, a total of 1,785 gene probes with significant prognostic differences were selected as seed genes. From these, 13 prognostic feature genes, including *COL28A1, PDS5A, ZDHHC2, ZNF24, MYO5A, MLLT4, NPR3, ANKH* and *OTUB1*, were further screened. The prognostic feature genes performed well for the classification of samples into different prognostic risk categories. Additionally, the GBM data set downloaded from the TCGA database further confirmed the association of the 13 prognostic feature genes with the prognosis of GBM.

Collagen XVI may promote the invasion of glioma cells by damaging cell-cell interactions or mediating the β1-integrin activation pattern, which provides new approaches for treating cancer in neuro-oncology ([@b33-mmr-19-03-1613]). Fibrillar collagens and the collagen internalization receptor, endocytic receptor 180 (Endo180), are overexpressed in GBM ([@b34-mmr-19-03-1613]). Additionally, Endo180 affects the invasion and progression of tumors ([@b34-mmr-19-03-1613]). Collagen type I α1 (*CO1A1*) was reported to serve a suppressive biological role in the progression of glioma, suggesting that it may be applied to treating the disease ([@b35-mmr-19-03-1613]). The COL28A1 protein is a filament-forming collagen and is detected in the adult sciatic nerve ([@b36-mmr-19-03-1613]). In our study, *COL28A1* was enriched in 'collagen biosynthesis and modifying enzymes' pathway. Therefore, *COL28A1* may serve a role in the progression of GBM.

*PDS5A* is tissue-specific and has two-fold effects in tumorigenesis, acting as a tumor suppressor or an oncogenic factor to promote tumor proliferation ([@b37-mmr-19-03-1613]). *PDS5A* was previously reported to be overexpressed in high-grade gliomas and is positively associated with the World Health Organization grade of gliomas ([@b37-mmr-19-03-1613]). Based on our enrichment result, *PDS5A* was involved in 'separation of sister chromatids' pathway, indicating it might influence the tumor\'s DNA synthesis phase in GBM development.

*ZDHHC2* on chromosome 8p21.3--22 belongs to the DHHC-domain protein family of protein acyltransferases ([@b38-mmr-19-03-1613]). As the largest transcription factor family in humans, zinc-finger proteins serve roles in multiple biological processes, including autophagy, metabolism, development and differentiation, and in cancer progression ([@b39-mmr-19-03-1613]). In addition, *ZDHHC2* is associated with prognosis in a number of types of cancer. In gastric cancer, decreased *ZDHHC2* expression is associated with lymph node metastasis and indicates a poor prognosis ([@b40-mmr-19-03-1613]). In the present study, *ZDHHC2* was highly associated with the 'surfactant metabolism' pathway and identified as a prognostic gene in GBM, suggesting that it might have an important role in GBM prognosis.

*ZNF24* plays a critical role in brain development and various cancer types. Furthermore, *ZNF24* may contribute to cell cycle promotion and maintenance of the progenitor stage of neural cells ([@b41-mmr-19-03-1613]). Platelet-derived growth factor receptor (PDGFR) signaling is a crucial mechanism for the initiation and development of GBM ([@b42-mmr-19-03-1613]). In GBM cell lines, *ZNF24* negatively regulates two transcription factors, vascular endothelial growth factor (VEGF) and PDGFR-β ([@b43-mmr-19-03-1613]).

In the present study, the above three genes were among the 13 crucial prognostic genes of GBM. The collective findings implicate *PDS5A, ZDHHC2* and *ZNF24* are involved in the pathogenesis of GBM. Although no studies have reported the potential roles of *ZDHHC2* in GBM, this gene may also be associated with the prognosis of GBM, based on our results.

Myosin II is required for the invasion of glioma cells and is a promising target for the anti-invasive treatment of malignant brain tumors ([@b44-mmr-19-03-1613],[@b45-mmr-19-03-1613]). In 1321N1 GBM cells, *MYO1C* is crucial for lamellipodia formation to produce a protein complex promoting cell migration ([@b46-mmr-19-03-1613]). *MYO6* was implicated in human glioma and its inhibition may be a promising therapeutic method for the disease ([@b47-mmr-19-03-1613]). The activation of myosin-associated contractility sensitizes GBM tumor-initiating cells, which subsequently weakens the invasive ability of the cells ([@b48-mmr-19-03-1613]). In the present study, *MYO5A* was enriched in 'regulation of actin dynamics for phagocytic cup formation'. Thus, *MYO5A* may serve a role in the progression of GBM.

*MLLT4* is one of the aliases of the gene, afadin, adherens junction formation factor, which belongs to an adhesion system and encodes a protein participating in cell junctions during embryogenesis. Neurofibromin 1 (*NF1*) mutations have been identified in several cancer types, including GBM ([@b49-mmr-19-03-1613]). Furthermore, in a mouse model of *NF1*-associated optic pathway gliomas (OPG), cyclic adenosine 3′,5′-monophosphate (cAMP) inhibits the growth of OPG ([@b50-mmr-19-03-1613]). Notably, *MLLT4* is one of the *NF1*-regulated effectors downstream of RAS ([@b51-mmr-19-03-1613]). Results from the present studies support the possible importance of *MLLT4* in GBM pathogenesis through the participation in the adherens junction, cAMP signaling and Ras signaling pathways. In addition, a number of pathways, such as leukocyte transendothelial migration, are enriched in GBM-derived extracellular vesicles (EVs), which suggested that GBM cells may exhibit mechanisms to selectively combine these proteins in EVs ([@b52-mmr-19-03-1613]). In the present study, leukocyte transendothelial migration was one of the six enriched pathways identified for MLLT3; therefore, this pathway may also be an important regulation target in GBM development. With regard to the tight junction pathway, junctional adhesion molecule (JAM) is one family of the immunoglobulin-like superfamily expressed in tight junctions, and abnormal JAM-A expression was reported to contribute to the progression of GBM ([@b53-mmr-19-03-1613]). This may be evidence of the gene expression alterations in the tight junction pathway in the development of GBM.

*NPR3* encodes a natriuretic peptide receptor, which regulates metabolic processes. A long noncoding RNA (lncRNA), BCYRN1, has an oncogenic role in colorectal cancer cells by upregulating *NPR3* expression ([@b54-mmr-19-03-1613]). In clear cell renal cell carcinoma (ccRCC), the lncRNA MRCCAT1 has been observed to promote ccRCC metastasis by inhibiting *NPR3* ([@b55-mmr-19-03-1613]). *ANKH* is identified as a novel putative oncogene in small cell lung cancer cell lines ([@b56-mmr-19-03-1613]). In cervical cancer, *ANKH* is also suggested as an oncogene and the upregulation is validated by reverse transcription-quantitative polymerase chain reaction ([@b57-mmr-19-03-1613]). To the best of our knowledge, there have been no studies reporting an association between these two genes, *NPR3* and *ANKH*, and glioma. However, in the present study, these were important prognostic genes of GBM and were enriched in crucial pathways, suggesting that they may be novel markers in GBM and correlate with prognosis.

The OTUB1 protein is a deubiquitinating enzyme. In glioma tissues, expression of *OTUB1* is increased and the expression level is associated with the glioma grade; on the other hand, knockdown of *OTUB1* suppresses the tumor cell migration ([@b58-mmr-19-03-1613]). This finding suggests that *OTUB1* serves an important role in the etiology of glioma ([@b58-mmr-19-03-1613]).

However, all these predictive results need to be further validated by *in vitro* and *in vivo* experiments. Notably, patients in the high-risk group were slightly older compared with patients in the low-risk group; although the difference was minor, it was significant. A previous study identified age as a risk factor for the process of dexamethasone-induced leukocytosis, which is associated with poor survival in the newly diagnosed GBM ([@b59-mmr-19-03-1613]). Therefore, the present study suggested that age may be a risk factor of GBM, but this needs to be validated using larger data sets.

In conclusion, the 13-gene set was tested and verified, and very efficiently predicted the prognosis of GBM in independent data sets. In addition, *COL28A1, PDS5A, ZDHHC2, ZNF24, MYO5A* and *MLLT4* were implicated as key genes involved in the prognosis of GBM. The adherens junction, cAMP and Ras signaling pathways may be important in the progression of GBM, and age may be a risk factor for prognosis.
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![Bioinformatics workflow. The GSE7696 dataset that comprised 70 primary GBM samples was downloaded from the GEO database. Upon filtering out the unloaded probes, a total of 1,785 probes were obtained; the corresponding genes were subjected to pathway enrichment analysis. A total of 13 prognostic feature genes were screened and subjected to unsupervised hierarchical clustering analysis and KM survival analysis. The TCGA dataset that included 152 primary GBM samples was used to validate the results of the 13 prognostic feature genes, and was subjected to multivariate survival analysis and KM survival analysis. GBM, glioblastoma multiforme; GEO, Gene Expression Omnibus; KM, Kaplan-Meier; TCGA, The Cancer Genome Atlas.](MMR-19-03-1613-g00){#f1-mmr-19-03-1613}

![Clustering heatmap for the 13 prognostic feature genes. The horizontal axis represents the samples, and the vertical axis represents the genes.](MMR-19-03-1613-g01){#f2-mmr-19-03-1613}

![Kaplan-Meier survival curve and expression correlations analysis for the 13 prognostic feature genes. (A) The survival curve of the two clusters. (B) The lower-left part is the scatter plot of the gene expression levels. The red to blue color in the upper-right part represent correlation coefficients ranging from −1 to +1, respectively. The diagonal line represents the expression distribution histogram of each gene. Asterisks indicate a correlation coefficient ≥0.45.](MMR-19-03-1613-g02){#f3-mmr-19-03-1613}

![Multivariate survival analysis for the 13 prognostic feature genes in the 70 primary GBM samples in GSE7696. (A) The AUC of multivariate survival analysis. (B) The Kaplan-Meier survival curve. AUC, area under the Receiver Operating Characteristic curve.](MMR-19-03-1613-g03){#f4-mmr-19-03-1613}

![Multivariate survival analysis for the prognostic feature genes in the 152 primary GBM samples in TCGA (validation data set). (A) The AUC multivariate survival analysis. (B) The Kaplan-Meier survival curve. AUC, area under the Receiver Operating Characteristic curve.](MMR-19-03-1613-g04){#f5-mmr-19-03-1613}

###### 

Pathways significantly enriched for the 1,785 seed genes.

  Term                                                   Count   P-value
  ------------------------------------------------------ ------- --------------
  hsa03010:Ribosome                                      43      2.31×10^−26^
  hsa04810:Regulation of actin cytoskeleton              27      4.09×10^−03^
  hsa05213:Endometrial cancer                            10      9.29×10^−03^
  hsa05200:Pathways in cancer                            34      2.08×10^−02^
  hsa00520:Amino sugar and nucleotide sugar metabolism     8     3.19×10^−02^
  hsa05223:Non-small cell lung cancer                      9     3.31×10^−02^

###### 

A total of 13 prognostic feature genes were identified from the 1,785 seed genes.

  Gene ID        nloglik   AIC      Gene
  -------------- --------- -------- ------------
  219789_at      198.94    399.87   *NPR3*
  215201_at      193.8     391.6    *REPS1*
  213254_at      190.47    386.95   *TNRC6B*
  225526_at      186.37    380.73   *MKLN1*
  223093_at      183.88    377.77   *ANKH*
  239921_at      180.76    373.52   *COL28A1*
  217331_at      177.81    369.62   *PDS5A*
  224685_at      177.78    371.55   *MLLT4*
  244779_at      176.76    371.52   *ZDHHC2*
  228786_at      176.17    372.34   *PTCHD3P1*
  201245_s\_at   175.81    373.63   *OTUB1*
  1554045_at     173.56    371.12   *ZNF24*
  204527_at      170.83    367.67   *MYO5A*

AIC, Akaike\'s information criterion; *ANKH*, ANKH inorganic pyrophosphate transport regulator; *COL28A1*, collagen type XXVIII α1 chain; ID, identification; *MKLN1*, muskelin 1; *MLLT4*, myeloid/lymphoid or mixed-lineage leukemia translocated to 4; *MYO5A*, myosin VA; *NPR3*, natriuretic peptide receptor 3; *OTUB1*, OTU deubiquitinase, ubiquitin aldehyde binding 1; *PDS5A*, PDS5 cohesin-associated factor A; *PTCHD3P1*, patched domain-containing 3 pseudogene 1; *REPS1*, PALBP1-associated EPS domain-containing 1; *TNRC6B*, trinucleotide repeat-containing 6B; *ZDHHC2*, zinc-finger DHHC-type containing 2; *ZNF24*, zinc-finger protein 24.

###### 

Age distribution of the samples in the high-risk and low-risk groups.

  Sample group       Min age   Mean age   Max age   Mann-Whitney test   Female   Male   P-value
  ------------------ --------- ---------- --------- ------------------- -------- ------ ---------
  High risk (n=95)   21        61.54      89        P=0.04396           32       64     P=0.51
  Low risk (n=57)    21        56.96      85                            22       35     
